Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:16:12.912Z.
Calculation as of: 2026-10-06T16:16:12.912Z.
Quote observation: 2026-10-06T16:13:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1c5d1a4dd2ed90e95308857a7b7df8ea0860f9bef9a655807fa9e02aea5f37e0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Cellectar Biosciences, Inc.
Market Cap
$12.86M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.89M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellectar Biosciences, Inc. (CLRB) | $12.86M | N/A | N/A | N/A | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $13.01M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.88M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.60M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.56M | N/A | 4.78 | 4.78 | 4.78 |
| Optimi Health Corp. (OPTH)vs › | $13.56M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.37M | N/A | 9.96 | 9.96 | 9.96 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.89M | N/A | N/A | N/A | N/A |
| IN8bio, Inc. (INAB)vs › | $13.89M | N/A | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.81M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
